Novan

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Novan sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).

18 total trials none currently recruiting 18 completed early-phase tilt top decile by trial count

Novan: 18 sponsored US clinical trials, none currently recruiting.

Novan sponsors 18 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 18 completed. 6 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 3 trials.

Top-decile sponsor footprint

Novan ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

18 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

18 total, page 1 of 1

COMPLETED Phase 3

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study

NCT04535531

COMPLETED Phase 3

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC

NCT03927703

COMPLETED Phase 3

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

NCT03927716

COMPLETED Phase 2

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

NCT03436615

COMPLETED Phase 1

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

NCT03431610

COMPLETED Phase 1

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

NCT03445013

COMPLETED Phase 1

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

NCT02801903

COMPLETED Phase 3

P3 Long Term Safety Study of Once Daily SB204 in Acne

NCT02798120

COMPLETED Phase 3

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

NCT02672332

COMPLETED Phase 3

P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne

NCT02667444

COMPLETED Phase 1

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

NCT02581072

COMPLETED Phase 2

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

NCT02462187

COMPLETED Phase 2

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

NCT02242760

COMPLETED Phase 1

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

NCT02250430

COMPLETED Phase 1

A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris

NCT02164084

COMPLETED Phase 1

A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel

NCT01844739

COMPLETED Phase 1

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

NCT01755247

COMPLETED Phase 1

Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers

NCT01694810

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 3
Phase 3 6

Therapeutic Areas

How the Novan early-phase archive is shaped

18 indexed studies, none listed as recruiting (0% open); 18 completed (100%).

Phase mix: 6 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Acne Vulgaris (3 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Novan: archived-pipeline peers nationwide

Peers matched on 18 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Novan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05101520 0%10%20%30%40% Total trials Recruiting share NovanADC Therapeutics S.A.Akros PharmaAO Clinical Investigation and Publishing DocumentationAO Innovation Translation Center10xBio22nd Century Group23andMe3-C Institute for Social Development
Novan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Novan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 18 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Novan page

18 registered trials is a research-attention snapshot, not an endorsement of Novan or any single study.

  • None of Novan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Acne Vulgaris is the condition Novan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Novan pipeline card: 18 registered trials from official public datasets.Report a data error.